Be the first to like this
Optimizing the utilization of Health Outcomes data has become increasingly important to the success of pharmaceutical and biotechnology companies. This study explores how U.S. biopharma organizations optimize and utilize Health Outcomes data both internally and externally. The study compares survey responses from 2009 and 2011 on questions around the utilization of Health Outcomes data. Some of the questions addressed in this report are which functional groups review Health Outcomes data, how HO data is used internally by different groups and how organizations use HO data externally. Executives and managers involved in utilizing Health Outcomes data can use this study to compare their procedures and tactics with leading organizations.